spacer
home > ebr > summer 2017 > in your genes
PUBLICATIONS
European Biopharmaceutical Review

In Your Genes

In April 2017, the FDA formally approved the sale of direct-to-consumer genetic testing for 10 disease indications and established a framework for future approvals. This opens up the field to consumer genetic tests that are both accurate in their readout and significant in their interpretation. It places the US market on the same playing field as Canada and UK – but the move is not without controversy.

Advances in genomics have stimulated great interest as a tool for drug discovery, as a means of disease diagnosis and treatment and as an additional way to make sense of individual prognoses. Particularly in the consumer health arena, breathtaking advances in science have captured the public imagination as a possible way to predict future health outcomes. As a sidebar, the ancestry interpretation of personal genomics has become very popular.

The recent FDA move concludes four years of restrictions placed on claims and product offerings by the personal genomics company 23andMe. This was a time to validate the accuracy of the lab work, scientific significance and clinical relevance and to address concerns about the consumer-facing documentation and interpretation. Doctors had often been faced with difficult patient questions like, ‘how much does this increase my risk?’

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, and an industry consultant, with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>

White Papers

Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.

Medpace

Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >>

 
Industry Events

T3: Trials, Tech and Transformation

30-31 May 2018, Raleigh Convention Center, Raleigh, NC

T3 is back for 2018 to provide you with the latest updates and top tips from across the clinical trials landscape. Connecting leading experts, influencers and innovators from pharma, biotech, CROs, patient advocacy groups, academia and beyond, T3 is themeeting place for all stakeholders to voice their questions, connect with peers, and get direct feedback from an expert speaker line-up.And this year, we're in Raleigh.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement